Medications

Harms reporting in trials of orlistat

The reporting of trials of orlistat in the 1990s appears to have understated harms, both in the summarized results submitted to the European Medicines Agency for drug approval, and in the published papers, according to a ...

Diabetes

Addition of orlistat benefits obese patients with T2DM

(HealthDay)—In overweight and obese patients with type 2 diabetes (T2D), treatment with orlistat in addition to lifestyle modifications improves outcomes, according to research published online Sept. 8 in Obesity Reviews.